The anti-PDL1 antibody drug pembrolizumab is being assessed in the neoantigen vaccine trial NCT03568058 in NSCLC, head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma (cHL) and other solid tumors. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.